

Cardiovascular

Tenecteplase




ElaximTM

*For use in the reduction of mortality
associated with acute myocardial
infarction (AMI).*

Analytical comparison with Innovator Product

Product Identity


- Peptide mapping
- Amino acid sequence coverage




Identical peptide map

Product purity


- SDS-PAGE



- Size exclusion HPLC




- Iso-electric focusing





Structural characterization

- Circular dichroism



- In-vitro potency assay



Periodic Safety Update Report

Between 2007 - 2018, submitted PSURs to the DCG(I), New Delhi includes data from 137157 patients.

Elaxim™ is approved for Acute Myocardial Infarction


We have affordable solution for :

- Cardiovascular diseases (CVDs), the number 1 cause of death globally, representing 31% of all deaths
- Over three quarters of CVD deaths which take place in low- and middle income countries


3rd Generation Thrombolytic

- Administered as a single bolus
- Dose: **0.2 mg/kg** body weight
- Longer half life of **18-22 min**
- **14 fold** greater fibrin specificity than alteplase
- **80 times** lesser susceptibility to PAI-1 than alteplase


Published efficacy and safety



The study conclusively establishes the safety and efficacy of indigenous TNK-tPA in Indian STEMI patients, including high-risk sub groups.




The findings of this study further reinforce the safety and efficacy of indigenous TNK-tPA in Indian patients presenting with STEMI, including high-risk sub groups.



In this retrospective, post-marketing assessment across India, 167 cardiologists from 102 centers across India participated. The study confirms that TNK-tPA is a safe and effective thrombolytic in Indian patients with STEMI. The major and minor bleeding complications are acceptable and comparable to available lytic drugs.

Pre-Hospital Thrombolysis (PHT)

- Reaching equipped hospital within the Golden Hour of 60-90 minutes from onset of heart attack is a challenge
- Any delay leads to progressive permanent damage to the heart
- PHT is an effort towards rapid diagnosis and treatment to save lives
- Mission Delhi was launched in April 2019 in collaboration with ICMR at AIIMS, New Delhi as a pilot study



Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the development, production and commercialization of bio-therapeutics to address life-threatening diseases across various indications. Incorporating recombinant DNA technologies together with innovative bio-manufacturing practices, Gennova has created cost effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology and oncology markets.